Abstract

Introduction

CoreTherm (ProstaLund AB, Lund, Sweden) is an outpatient treatment option in men with lower urinary tract symptoms and catheter-dependent men with chronic urinary retention caused by benign prostatic obstruction (BPO). CoreTherm is high-energy transurethral microwave thermotherapy with feedback technique. Modern treatment with CoreTherm includes transurethral intraprostatic injections of mepivacaine and adrenaline via the Schelin Catheter (ProstaLund AB, Lund, Sweden) and is often referred to as the CoreTherm Concept.

Objectives

The aim of this study was to evaluate the short- and long-term retreatment risk in men with large prostates and BPO or chronic urinary retention, all primarily treated with CoreTherm.

Material and Methods

All men from the same geographical area with prostate volumes ≥ 80 ml treated 1999–2015 with CoreTherm and having BPO or were catheter-dependent due to chronic urinary retention, were included. End of study period was defined as December 31, 2019.

Results

We identified and evaluated 570 men treated with CoreTherm, where 12% (71 patients) were surgically retreated during the follow-up. Mean follow-up was 11 years, and maximum follow-up was 20 years. The long-term retreatment rate in our study was 23%. A majority of these could be retreated with CoreTherm or TURP, with only 3% requiring open surgery.

Conclusion

We conclude that CoreTherm is a suitable outpatient treatment option in patients with profoundly enlarged prostates, regardless of age, prostate size, and reason for treatment.

中文翻译：

---

CoreTherm 治疗 570 例前列腺体积为 80-366 毫升的患者：短期和长期再治疗风险的评估

摘要

介绍

CoreTherm（ProstaLund AB，瑞典隆德）是一种门诊治疗选择，适用于患有下尿路症状的男性和因良性前列腺梗阻 (BPO) 引起的慢性尿潴留的导管依赖型男性。CoreTherm 是采用反馈技术的高能经尿道微波热疗。CoreTherm 的现代治疗包括通过Schelin 导管（ProstaLund AB，Lund，瑞典）经尿道前列腺内注射甲哌卡因和肾上腺素，通常被称为 CoreTherm 概念。

目标

本研究的目的是评估患有大前列腺和 BPO 或慢性尿潴留的男性的短期和长期再治疗风险，所有这些都主要使用 CoreTherm 治疗。

材料与方法

来自同一地理区域的所有男性在 1999-2015 年接受 CoreTherm 治疗并患有 BPO 或因慢性尿潴留而依赖导管的前列腺体积 ≥ 80 ml。研究期结束日期定义为 2019 年 12 月 31 日。

结果

我们确定并评估了 570 名接受 CoreTherm 治疗的男性，其中 12%（71 名患者）在随访期间接受了手术治疗。平均随访时间为 11 年，最长随访时间为 20 年。在我们的研究中，长期复治率为 23%。其中大部分可以使用 CoreTherm 或 TURP 进行再治疗，只有 3% 需要开腹手术。

结论

我们得出的结论是，无论年龄、前列腺大小和治疗原因如何，CoreTherm 都是前列腺严重肿大患者的合适门诊治疗选择。